Mobile

Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator Estudio para pe...

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-004707-12

Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator Estudio para permitir el acceso a everolimus a pacientes que estén recibiendo tratamiento con everolimus en un estudio patrocinado por Novartis y que, a criterio del investigador, se estén beneficiando del tratamiento

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To allow continued use of everolimus to patients receiving everolimus in a Novartis-sponsored Oncology CD&MA study which has reached its objectives and who are benefitting from treatment with everolimus as defined in the parent protocol Permitir el uso continuado de everolimus a pacientes que reciban everolimus en un estudio de CD&MA de Oncología patrocinado por Novartis, en el que hayan alcanzado sus objetivos y se estén beneficiando del tratamiento con everolimus. Recoger datos a largo plazo sobre acontecimientos adversos graves

Critère d'inclusion

  • Disease corresponding to the Novartis-sponsored study the patient will be transitioning from,Enfermedades correspondientes al estudio patrocinado por Novartis

Liens